Document:

xene-ex1019_115.htm

 

Exhibit 10.19

LEASE MODIFICATION AGREEMENT

This lease modification agreement (hereinafter referred to as this “Agreement” or the “Eighth Modification”) is made on the 14th Day of December, 2015 and made effective the 1st day of December, 2015 (the “Effective Date”). 

BETWEEN:

REDSTONE ENTERPRISES LTD.

(the “Landlord”)

AND:

XENON PHARMACEUTICALS INC.

(the “Tenant”)

WHEREAS:

	
A.
	
By a lease made in 2001 (the “Original Lease”) between Discovery Parks Incorporated (the “Original Landlord”) and Xenon Genetics Inc. (the “Original Tenant”), the Original Tenant leased certain premises (the “Original Premises”) comprising the whole of the building (the “Building”) located on property known as 3650 Gilmore Way, Burnaby, British Columbia, as more particularly described in the Original Lease for a term of ten (10) years expiring on April 14, 2011;

	
B.
	
Concert Real Estate Corporation (the “Previous Landlord”) was the immediate successor in interest to the Original Landlord; the Landlord is the successor in interest to the Original Landlord and the Previous Landlord;

	
C.
	
The Tenant is the successor in interest to the Original Tenant;

	
D.
	
By a lease extension and modification agreement made effective November 8, 2010 (the “First Modification”) between the Previous Landlord and Tenant, the Previous Landlord and the Tenant agreed to extend the term of the Original Lease for an additional four (4) months and sixteen (16) days, for a term expiring on August 31, 2011, as further described in the First Modification; 

	
E.
	
By a lease extension and modification agreement made effective February 7, 2011 (the “Second Modification”) between the Previous Landlord and Tenant, the Previous Landlord and the Tenant agreed to extend the term of the Original Lease for an additional four (4) months, for a term expiring on December 31, 2011, as further described in the Second Modification;

	
F.
	
By a lease extension and modification agreement made effective June 1, 2011 (the “Third Modification”) between the Previous Landlord and Tenant, the Previous Landlord and the Tenant agreed to extend the term of the Original Lease for an additional three (3) months, for a term expiring on March 31, 2012, as further described in the Third Modification; 

Page 1 of 8

 

	
G.
	
By an Offer to Lease (the “Original Offer”) accepted by the Previous Landlord on November 9, 2010 and accepted by the Tenant on November 23, 2010, the Previous Landlord and Tenant agreed that the Tenant would continue to lease a portion (the “Proposed New Premises”, being the whole of the 1st and 2nd floors of the Building) of the Original Premises, as more particularly described in the Offer, for a term of 120 months commencing on September 1, 2011, on the terms and conditions set out in the Original Offer; 

	
H.
	
By an Addendum/Amendment (the “First Addendum”) dated for reference February 7, 2011, the Original Offer was amended as set out therein; 

	
I.
	
By an Addendum/Amendment (the “Second Addendum”) dated for reference June 1, 2011, the Original Offer, as amended, was further amended as set out therein;

	
J.
	
By an Addendum/Amendment (the “Third Addendum”) dated for reference August 31, 2011, the Original Offer, as amended, was further amended as set out therein, including adding a right for the Tenant to elect to surrender and terminate its rights under the Original Offer in respect of that portion (the “Surrender Area”) of the Proposed New Premises shown on the plan attached to the Third Addendum as Exhibit A; 

	
K.
	
By an Addendum/Amendment (the “Fourth Addendum”) dated for reference September 30, 2011, the Original Offer, as amended, was further amended by replacing the plan of the Surrender Area attached to the Third Addendum as Exhibit A with the plan attached as Exhibit A to the Fourth Addendum;

	
L.
	
By a letter (the “Surrender Letter”) dated September 30, 2011, the Tenant notified the Previous Landlord that the Tenant was exercising its right to surrender and terminate its rights under the Original Offer in respect of the Surrender Area;

	
M.
	
The Original Offer, as amended by the First Addendum, Second Addendum, Third Addendum, Fourth Addendum,  the Surrender Letter, Addendum #5 dated October 19, 2011, Addendum #6 dated October 28, 2011, Addendum #7 dated November 9, 2011, Addendum #8 dated November 25, 2011, and Addendum #9 dated November 29, 2011 is herein referred to as the “Offer” and the Proposed New Premises, excluding the Surrender Area but including the IT Room (as defined below) are referred to as the “Premises”;

	
N.
	
By a lease extension and modification agreement made as of October 27, 2011 (the “Fourth Modification”) as amended by a lease modification agreement made as of April 1, 2012 (the “Fifth Modification”) each between the Previous Landlord and Tenant, the Previous Landlord and the Tenant agreed to extend the term of the Original Lease for an additional ten (10) years, for a term expiring on March 31, 2022 on the terms and conditions therein, as further described in the Fourth Modification and Fifth Modification (the Original Lease as modified by the First Modification, the Second Modification, the Third Modification, the Fourth Modification, and the Fifth Modification is referred to herein as the “Lease”);

	
O.
	
By a lease modification agreement made as of July 18, 2014 (the “Sixth Modification”) between the Landlord and the Tenant, the Landlord and the Tenant agreed to amend the rentable area, by an additional 3,000 square feet of rentable area, to include a portion of the third floor referenced therein as “Unit 310A”, and as further described in the Sixth Modification (the Original Lease as modified by the First Modification, the Second Modification, the Third Modification, the Fourth Modification, the Fifth Modification, and the Sixth Modification is referred to herein as the “Lease”)’

	
P.
	
By a lease modification agreement made as of June 26th, 2015 (the “Seventh Modification”) between the Landlord and the Tenant, the Landlord and the Tenant agreed to amend the rentable area, by an additional 2,737 square feet of rentable area, to include a portion of the third floor referenced therein as 

Page 2 of 8

 

		
“Unit 310B”, and as further described in the Seventh Modification (the Original Lease as modified by the First Modification, the Second Modification, the Third Modification, the Fourth Modification, the Fifth Modification, the Sixth Modification and the Seveneth Modification is referred to herein as the “Lease”)’ 

	
Q.
	
The Landlord is the successor in interest to the Original Landlord and the Previous Landlord;

	
R.
	
The Landlord and the Tenant acknowledge and agree that the recitals hereto are true and incontrovertible;

	
S.
	
The Landlord and the Tenant have agreed to amend the Lease on the terms set out herein.

THEREFORE in consideration of the premises, the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each of the parties hereto, the parties agree as follows:

	
1.
	
For the purposes of this Agreement and unless there is a definition specifically herein contained, any words, terms or phrases that are defined in the Lease shall have the same meaning herein.

	
2.
	
Effective on the Effective Date, the Landlord and the Tenant agree that the Rentable Area and all payments related thereto in the Lease shall be adjusted in accordance with this Agreement.

	
3.
	
As of the Effective Date, the Landlord and the Tenant agree to delete Clause 3 of the Seventh Modification and replace it with the following:

“The Landlord and the Tenant agree to delete Clause 2(a) of the Fourth Modification and replace it with the following: 

(a) In section 1.1, the phrase “Rentable Area of approximately 56,776 square feet, being the entire Building situated thereon, as set out in Schedule “A” attached hereto” is deleted and replaced with “Rentable Area of 41,332 square feet, being a portion of the first floor (Unit 120), the entire second floor (Unit 200),  and a portion of the third floor (“IT Room” and “Unit 200” and the adjacent contiguous portions of Unit 310 referenced as “Unit 310A”, “Unit 310B” and “Unit 310C”) of the Building situated thereon, each as set out in Schedule “A” attached hereto, and includes the Tenant’s Proportionate Share of Common Areas as per section 3.3 below.  For avoidance of doubt, the areas designated as “Vertical Penetrations Areas” in Schedule “A” and Schedule “E” are not included in the “Second Measurement” calculation underlying the above-noted Rentable Area and the Basic Rent set forth in Section 3.1 below.”;

Page 3 of 8

 

	
4.
	
As of the Effective Date, the Landlord and the Tenant agree to amend Clause 4 of the Seventh Modification to add the following costs with respect to Unit310C: 

The following is added at the bottom of the table set out therein and the costs described in the table shall be in addition to the costs provided for in the Seventh Amendment: 

 

				
	
Period
	
Per Square

Foot of

Unit310C
	
Basic Rent for Unit 310C Per Annum
	
Basic Rent for Unit 310C Per Month

	
June 1st, 2016 to

May 31st, 2017
	
$14.50
	
$72,427.50
	
$6,035.63

	
June 1st, 2017 to

May 31st, 2018
	
$15.00
	
$74,925.00
	
$6,243.75

	
June 1st, 2018 to

May 31st, 2019
	
$15.50
	
$77,422.50
	
$6,451.88

	
June 1st, 2019 to

May 31st, 2020
	
$16.00
	
$79,920.00
	
$6,660.00

	
June 1st, 2020 to

May 31st, 2021
	
$16.50
	
$82,417.50
	
$6,868.13

 

The Tenant shall have a Free Rent Period on Unit 310C from December 1, 2015 through to May 31, 2016.  During this period, the Tenant shall not pay to the Landlord the Proportionate Share of Operating Expenses and property taxes related to Unit 310C unless the Tenant occupies any portion of Unit310C. 

For clarity, the Landlord and the Tenant confirm and agree that, the Allowance referenced in clause 5 of the Fourth Modification, clause 10 of the Fifth Modification and clause 7 of the Sixth Modification is applicable to any Tenant’s Leasehold Improvements that the Tenant may make to any portion of the Premises that comprises the Rentable Area as of the Effective Date, including Unit 310C.  

	
5.
	
The Landlord acknowledges and agrees that, notwithstanding anything to the contrary in the Lease, as of the Effective Date, with respect to the third (3rd) floor of the Building, Section 8.4 of the Lease shall be interpreted to apply only to those business and trade fixtures, machinery and equipment, cabinet work, furniture and moveable and immovable partitions owned or installed by the Tenant after the Effective Date. 

	
6.
	
The Landlord and the Tenant agree to delete Article 35 from the Lease in its entirety and replace it with the following:

“35.0 RIGHTS OF TERMINATION

35.1 Provided that the Tenant has not been in material breach of the Lease, the Tenant shall have one (1) right to surrender the Lease, for all spaces except for Unit 310C, on or at any time after March 31, 2015 (the “Right to Terminate”) by providing a minimum of twelve (12) months prior written notice to the Landlord and, upon providing written notice to cancel the Lease, paying a surrender fee calculated as the unamortized portion of the contribution paid by the Landlord to the Tenant in relation to the extention of the Term for the period from April 1, 2012 to March 31, 2022, being Twenty-five dollars ($25.00) per square foot or Rentable Area of the Premises (the “Allowance”), the unamortized portion of real estate commissions paid by the landlord, and two (2) months’ Rent, plus applicable taxes.  Real estate commissions shall not be 

Page 4 of 8

 

applicable to Unit 310A and Unit 310B.  For the purpose of this calculation, the Allowance and commission shall be amortized over the period from April 1, 2012 to March 31, 2022 at an effective interest rate of 7% per annum, compounded semi-annually.  The Tenant may use this one (1) right to surrender at its sole discretion:

	
 
	
-
	
Only unit 310A; 

	
 
	
-
	
Only unit 310B;

	
 
	
-
	
Units 301A and 310B together; or

	
 
	
-
	
The entire Premises, i.e. 1st Floor, 2nd Floor, Unit 310A and Unit 310B. 

The Tenant agrees that after using this one (1) right to surrender, the Tenant shall no longer have any rights to surrender the Lease, except for the right as described in Section 35.2 of this Lease.  

35.2 Provided that the Tenant has not been in material breach of the Lease, the Tenant shall also have one (1) right to surrender the Lease for Unit 310C only, effective June 1, 2016.  As a penalty to surrender Unit 310C, the Tenant shall pay out the balance of the Rent due for the Term of the Lease, subtracting twelve (12) months, for Unit 310C (The “Unit 310C Termination Penalty”) plus applicable taxes.  If any portion of the Allowance has been used towards Unit 310C then the Tenant shall also pay the unamortized portion of the Allowance based on the terms and conditions outlined in this Article 35.  For greater clarification real estate commissions are not applicable to Unit 310C.”

	
7.
	
Notwithstanding anything to the contrary in the Lease, the Landlord hereby agrees that Tenant may, upon notice to the Landlord, sublease the Premises, on any portion thereof.

	
8.
	
The Landlord and the Tenant agree that Schedule “A” of the Lease is deleted and replaced with Schedule “A” attached hereto.

	
9.
	
The parties confirm and ratify the terms and conditions contained in the Lease as amended by this Agreement.

	
10.
	
This Agreement will, from the Effective Date, be read and construed together with the Lease, and the Lease, as amended hereby, shall continue in full force and effect for the remainder of the term of the Lease in accordance with the terms thereof and hereof.  

	
11.
	
This Agreement will enure to the benefit of and be binding upon the heirs, executors, administrators, successors and permitted assigns of the parties.

	
12.
	
This Agreement may be signed in counterparts, and delivered personally or by courier, mail, facsimile or electronically, each of which counterparts when executed by any of the signatories hereto shall be deemed to be an original and such counterparts shall together constitute one and the same Agreement.

Page 5 of 8

 

IN WITNESS WHEREOF the parties have executed this Agreement as of the date first above written. 

REDSTONE ENTERPRISES LTD.

 

	
By:
	
 
	
/s/ Ali Nanji

	
 
	
 
	
Ali Nanji

	
 
	
 
	
President

 

	
By:
	
 
	
/s/ Zahir Rajani

	
 
	
 
	
Zahir Rajani

	
 
	
 
	
Director of Leasing & Operations

 

XENON PHARMACEUTICALS INC.

 

	
By:
	
 
	
/s/ Ian Mortimer

	
 
	
 
	
Ian Mortimer

	
 
	
 
	
Chief Financial Officer & Chief Operating Officer

Page 6 of 8

 

schedule “a”

PLAN

1st Floor – Unit 120

 

 

2nd Floor – Tenant is leasing entire 2nd Floor

 

 

Page 7 of 8

 

3rd Floor – IT Room, Unit 200 & Unit 310A, 310B and 310C

 

 

	
 
	
·
	
The portion of Unit 310 that is outlined in orange above, is Unit 310A, the portion that is outlined in red is Unit 310B, and the portion that is outlined in green is Unit 310C.

END OF DOCUMENT

Page 8 of 8xene-ex1020_114.htm

 

Exhibit 10.20

 

Genentech

A Member of the Roche Group

 

November 19, 2015

 

Xenon Pharmaceuticals Inc

Attention: President and Chief Executive Officer 

3650 Gilmore Way

Burnaby, BC 

V5G 4W8

 

And to

 

Xenon Pharmaceuticals Inc.

Attention General Counsel and Corporate Secretary 

3650 Gilmore Way

Burnaby, BC 

V5G 4W8

 

Re: Letter Agreement for NaV1.7 Research Term Extension Dear Dr. Pimstone,

This letter refers to that certain Collaborative Research and License Agreement between Xenon Pharmaceuticals Inc. ("Xenon"), Genentech Inc. ("Genentech") and F. Hoffmann-La Roche Ltd. ("Roche") effective December 22, 2011, the "Agreement".

Capitalized terms used in this Letter have the definitions set forth in the Agreement.

In accordance with Section 2.4 of the Agreement, the Parties hereby agree to extend the Research Program for an additional [†] commencing on [†] and ending on [†], the "Second Extended Research Term".   At any time between [†] and [†], Genentech may terminate the Second Extended Research Term with 30 day written notice to Xenon.

During the Second Extended Research Term, the Parties agree and acknowledge as follows:

"Research Plan" means the written plan of research activities to be conducted by or on behalf of the Parties pursuant to the Agreement as further described in Section 3.6.

The initial Research Plan is amended according to Sections 2.3 and 2.4, to include the further activities described in Appendix A attached hereto.

"FTE Rate" shall mean .the amount Genentech will pay to Xenon over a consecutive twelve (12) month period during the Second Extended Research Term to support one (1) Xenon FTE dedicated to the Research Plan.  The FTE Rate shall be USD $[†] for the [†] FTEs funded during the Second Extended Research Term.  The FTE Rate represents a [†]% increase compared to the previous FTE Rate based on the annual Consumer Price Index change from September 2014 through September 2015 (http:www.statcan.gc.ca/tables-tableaux/sum-som/101/cslO1/cpis02a-eng.com) as required in the Agreement.

All other terms of the Agreement shall remain in full force and effect.

[†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

This letter may be signed in counterparts and delivered personally or by courier, mail, facsimile, or electronically, each of which counterparts when executed by any of the signatories hereto shall be deemed to be an original and such counterparts shall together constitute one and the same agreement.

In Witness Whereof, the Parties have caused this Letter to be executed by their respective duly authorized representatives set forth below, and it shall be effective as of November 19, 2015.

 

	
Xenon Pharmaceuticals Inc.
	
 
	
Genentech Inc.

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
/s/ Robin Sherrington
	
 
	
By:
	
 
	
/s/ Bruce D Roth

	
Name:
	
 
	
Robin Sherrington
	
 
	
Name:
	
 
	
Bruce D Roth

	
Title:
	
 
	
Senior VP Business and
	
 
	
Title:
	
 
	
Senior VP Research

	
 
	
 
	
Corporate Development
	
 
	
 
	
 
	
 

 

[†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

Appendix A

 

Xenon Pharmaceuticals Inc.,

&

Genentech, Inc.,

 

Research Plan

November 9, 2015

 

[†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

	
1.
	
BACKGROUND 

This research plan outlines the activities of the collaborative Research Program.  [†].

[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
2.
	
ACTIVITY 1: [†]

[†]

[†]

[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

[†]

	
3.
	
ACTIVITY 2: [†]

[†]

[†]

[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

	
 
	
•
	
[†]

[†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

	
 
	
•
	
[†] 

	
 
	
•
	
[†]

	
 
	
•
	
[†]

[†]

 

 

 

[†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

 

Xenon FTEs

 

	
Department
	
Xenon FTEs
	
Activities of Xenon FTEs

	
[†]
	
[†]
	
●       [†]

●       [†]

●       [†]

●       [†]

●       [†]

	
[†]
	
[†]
	
●       [†]

●       [†]

	
[†] I [†]
	
[†]
	
●       [†]

●       [†]

●       [†]

●       [†]

●       [†]

●       [†]

 

 

[†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]